Bristol-Myers Squibb (BMY) received the US Food and Drug Administration's full approval for Opdivo plus Yervoy as a first-line treatment for adults with unresectable or metastatic hepatocellular carcinoma, a form of liver cancer.
The approval was supported by results from a phase 3 trial, which demonstrated that the combination therapy significantly improved overall survival to 23.7 months, compared with 20.6 months with lenvatinib or sorafenib, reducing the risk of death by 21%, the company said Friday in a statement.
The trial's safety analysis involved 657 patients with 332 receiving Opdivo plus Yervoy, and 53% of those patients experienced serious adverse reactions, the company said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。